Business Wire

World Parkinson’s Day 2020: BIAL launches new campaign ‘Don’t let Parkinson’s stop you. Keep on moving’

Share

BIAL Pharmaceuticals has created a new film for World Parkinson’s Day 2020 to dispel the stigma around Parkinson’s and show the amazing achievements, breadth and diversity of people living with the condition. The film, “Keep on moving”, is the latest part of a worldwide campaign, launched by BIAL four years ago. The campaign aims to increase awareness and knowledge of Parkinson's Disease and to inspire and empower millions of people living with Parkinson’s around the world.

Parkinson’s is a neurodegenerative disease that affects as many as 1.2 million people in Europe alone.1 As the disease progresses, everyday tasks such as bathing, dressing, eating, sleeping and even walking can become real challenges.2 The film aims to show that, despite this, Parkinson’s doesn’t need to define a person.

It features consecutive sets of people doing what they love, whether it be playing the guitar, drumming, drawing or cooking. One person in each set has Parkinson’s and one does not. The focus is on what makes people with Parkinson’s disease amazing rather than what makes them different. The hope is that by sharing these incredible stories it will help everyone to appreciate what people with Parkinson’s are capable of overcoming and inspire others to recognise that they are much more than their disease.

Rui Sobral, Head of BIAL’s Global Parkinson’s Department, comments: "Although Parkinson’s changes people’s lives, it’s important people don’t limit themselves or lose their self-esteem because of it. With this campaign we wanted to counter the negative portraits of people with Parkinson’s and show everyone what they can achieve. We hope the film encourages and empowers the millions of people living with Parkinson’s to never give up on pursuing their individual passions and ‘keep on moving’.”

Since 2017, BIAL has developed global campaigns associated with World Parkinson's Day to increase awareness of the disease and how it affects people directly and indirectly. The films, that have had more than 1,1 million views to date, also aim to depict how some of the limitations associated with the disease can be overcome with the understanding and support of all. Films include:

- 2020: Keep on moving
- 2019: Speak up for Parkinson's
- 2018: There's no right rhythm for life
- 2017: Me at my best

References
1. ICM Institute. Neurogenerative Diseases. Available at https://icm-institute.org/en/key-figures/. Accessed March 2020
2. Parkinson’s Foundation. Activities of Daily Living. Available at https://www.parkinson.org/Living-with-Parkinsons/Managing-Parkinsons/Activities-of-Daily-Living. Accessed March 2020

__________________________________________________________________

About BIAL
Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide. For more information on BIAL: www.bial.com

About Parkinson’s Disease
Parkinson's disease is a chronic, progressive neurodegenerative disorder characterised by a strong reduction of the neurotransmitter dopamine, caused by the degeneration of certain neurons in the brain. Epidemiological evidence highlights a complex interaction between genetic vulnerability and environmental factors. The clinical manifestations usually appear after the age of 50 years (the average age of diagnosis is approximately 60 years). The prevalence of the disease is estimated at 300 per 100,000 inhabitants, increasing to 1 in 100 in the age group between 55 and 60 years. The European Parkinson's Disease Association (EPDA) estimates that approx. 1.2 million people suffer from this disease in the European Union. The diagnosis of Parkinson's disease is based on clinical observation and relies on three key elements: bradykinesia (slow movements), resting tremor, and rigidity (muscle stiffness). Of these, bradykinesia must be present, with at least either tremor or rigidity. Other common symptoms are postural instability, reduced facial expression and blinking, and a slouching posture. The disease progressively incapacitates patients, causing hindrance in their lives and daily activities.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Enquiries
Susana Vasconcelos
T. +351 229866100 | E. susana.vasconcelos@bial.com

Grainne Maguire
T: +44 (0) 7799380801 | E. grainne@makarahealth.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Boomi Doubles Down on API Management with Key Acquisitions8.5.2024 19:00:00 EEST | Press release

Boomi™, the intelligent integration and automation leader, today announced the acquisitions of APIIDA’s federated API management business and API management assets from Cloud Software Group, allowing enterprises to rapidly and securely deliver business value through API products in one end-to-end platform. Both these acquisitions accelerate Boomi’s roadmap for providing solutions to the most pressing API management challenges that companies face today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508324428/en/ Boomi Doubles Down on API Management with Key Acquisitions (Graphic: Business Wire) “APIs are the backbone of modern software and application development, and have become a cornerstone of modern architectures that enable businesses to stay agile and compete effectively,” said Steve Lucas, CEO at Boomi. “However, cloud adoption and the explosive growth of APIs have disrupted traditional IT infrastructures. With the

Boomi Unveils New Vision with Strategic Acquisitions and Latest Innovations at Boomi World 20248.5.2024 19:00:00 EEST | Press release

Boomi™, the intelligent integration and automation leader, today unveiled its vision for the company’s future, along with strategic acquisitions and key product announcements at Boomi World 2024. With more than 20,000 global customers and a network of approximately 800 partners worldwide, Boomi is leading the industry towards the future with a focus on integration and automation, API management, and data management, all made more important and powerful than ever with the emergence of the AI economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508488304/en/ Boomi Unveils New Vision with Strategic Acquisitions and Latest Innovations at Boomi World 2024 (Graphic: Business Wire) In his keynote, Boomi CEO Steve Lucas emphasized the transformative impact of integration platform as a service (iPaaS), spotlighting its pivotal role in enhancing speed, agility, and effectiveness across business operations. Lucas explained how Bo

The smarter E AWARD 2024: Finalists Present Pioneering Solutions for a Renewable 24/7 Energy Supply8.5.2024 18:39:00 EEST | Press release

The energy industry is undergoing a radical transformation. Renewable sources of energy have become increasingly profitable in recent years and are now the most economically viable solution for generating electricity. Deployment is accelerating and the technologies are becoming increasingly sophisticated. This has put renewables in the fast lane. Visionary companies are contributing to this development with modern technologies, ideas and concepts. The best and most innovative developments have been nominated for The smarter E AWARD 2024. The prize is awarded in five categories: Photovoltaics, Energy Storage, E-Mobility, Smart Integrated Energy and Outstanding Projects. The winners will be honored on the eve of The smarter E Europe on June 18 at 6:15pm at the International Congress Center München (ICM). Europe’s largest alliance of exhibitions for the energy industry unites four exhibitions (Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe) and will take place at Me

Empowering Excellence Through AI Enablement: HTEC Invests in a 100% AI-fluent Workforce8.5.2024 17:16:00 EEST | Press release

HTEC, a global digital consulting, software engineering, and product development firm, has launched an organization-wide AI enablement initiative. The initiative aims to equip HTEC’s global workforce with fundamental and highly technical artificial intelligence (AI) capabilities and provide continuing education in AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508019530/en/ HTEC announces AI enablement program (Photo: Business Wire) Bringing each HTEC employee to the necessary level of AI literacy is crucial — it enables the organization to continue leading AI-powered digital transformations for its clients and ensure the productivity and effectiveness of its workforce while doing so. “To lead and transform our customers, we must transform ourselves. Prioritizing hands-on experience and continuous learning is necessary to stay ahead in AI. The HTEC AI Enablement program will seamlessly guide our teams into the new AI

Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML8.5.2024 17:00:00 EEST | Press release

A groundbreaking research study,1 sequencing DNA samples from the Pre-MEASURE study2 strongly indicates that the detection of residual FLT3 internal tandem duplication (ITD) mutations in the blood of adult subjects with acute myeloid leukemia (AML) in first complete remission (CR) is associated with worse outcomes after post allogeneic hematopoietic cell transplant (HCT). This follow-up study performed measurable residual disease (MRD) testing on DNA of 537 subjects with FLT3-ITD AML from the Pre-MEASURE study using Invivoscribe’s RUO FLT3 ITD MRD Assay kit and bioinformatics software. Its findings underscore the likely significance of residual FLT3-ITD in first CR in predicting relapse and mortality post-transplant. A key finding from this research study was that AML subjects with residual FLT3-ITD detected prior to allogeneic HCT trended towards elevated risk of relapse and mortality post-transplant, with a dose-dependent correlation within this study population. Dr. Hourigan, Direct

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye